MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 90.48% from the company's current price.
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Needham & Company LLC restated a "buy" rating and set a $62.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, September 12th. Wolfe Research downgraded MoonLake Immunotherapeutics from an "outperform" rating to a "peer perform" rating in a report on Monday, August 26th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $78.80.
Read Our Latest Stock Analysis on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Stock Performance
Shares of MLTX stock traded up $1.44 during trading hours on Thursday, reaching $52.50. The company had a trading volume of 213,152 shares, compared to its average volume of 374,025. The stock's fifty day simple moving average is $49.68 and its 200 day simple moving average is $45.62. The company has a market capitalization of $3.35 billion, a P/E ratio of -39.58 and a beta of 1.28. MoonLake Immunotherapeutics has a twelve month low of $37.35 and a twelve month high of $64.98.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). During the same quarter last year, the business earned ($0.18) EPS. As a group, equities analysts expect that MoonLake Immunotherapeutics will post -1.74 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Simon Sturge sold 171,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the sale, the director now directly owns 171,980 shares in the company, valued at $9,238,765.60. The trade was a 49.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.02% of the stock is currently owned by insiders.
Institutional Investors Weigh In On MoonLake Immunotherapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter worth $44,000. Quarry LP raised its position in MoonLake Immunotherapeutics by 172.7% in the second quarter. Quarry LP now owns 3,000 shares of the company's stock worth $132,000 after acquiring an additional 1,900 shares in the last quarter. Bellevue Group AG acquired a new stake in MoonLake Immunotherapeutics in the 1st quarter valued at about $221,000. DNB Asset Management AS boosted its position in shares of MoonLake Immunotherapeutics by 29.8% during the 2nd quarter. DNB Asset Management AS now owns 7,372 shares of the company's stock valued at $324,000 after purchasing an additional 1,694 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of MoonLake Immunotherapeutics by 26.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company's stock worth $655,000 after purchasing an additional 2,700 shares during the last quarter. Institutional investors own 93.85% of the company's stock.
MoonLake Immunotherapeutics Company Profile
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
